Ceribell Inc

CBLL remains in a medium-term bullish Stage 2 advance, driven by an accelerating parabola structure. Price is holding just above the rising 9-day EMA after a shallow pullback, with EMAs stacked and momentum intact. RSI has eased from extreme overbought, suggesting room for consolidation or renewed upside. The path of least resistance remains higher, favoring entries near EMA support.

• ↑CBLL leads neurological diagnostics with digital health market tailwinds
• ↑1.62% dividend yield appeals to income-oriented investors
• ↓EPS fell short of estimates, causing a 0.8% share decline